Lamictal (Lamotrigine) and Kidney Function: Safety and Monitoring

Lamotrigine (Lamictal) is primarily metabolized by hepatic glucuronidation (UGT1A4). Renal excretion of unchanged drug is minimal (~10%).

Kidney Safety Profile

  • No significant nephrotoxicity in clinical trials or post-marketing
  • Safe in mild–moderate CKD (eGFR 30–89 mL/min) without dose adjustment
  • In severe CKD (eGFR <30) or ESRD on dialysis: limited data; consider dose reduction (↓25–50%) and monitor for adverse effects (rash, dizziness, ataxia)
  • Hemodialysis removes some lamotrigine; post-dialysis supplemental dose may be needed

Clinical Recommendations

  • Inform prescriber of any kidney disease
  • Baseline and periodic renal function monitoring if CKD present
  • Do not adjust or stop without medical supervision (risk of seizure recurrence, withdrawal)
  • Watch for drug interactions: valproate ↑ lamotrigine levels; carbamazepine/phenytoin ↓ levels

Overall, lamotrigine is considered kidney-friendly among antiseizure medications.

Kidney Disease - Related Articles